Advancing precision medicine with molecular glues
Magnet Biomedicine’s modular TrueGlue™ technology enables the systematic discovery of molecular glues toward the treatment of human disease.
The Science
TrueGlues are small molecules that localize drug effects to disease-relevant targets in complex with tissue-enriched “presenter” proteins.
Magnet is advancing precision medicine through the rational selection of protein pairs and systematic design of monovalent molecular glues. Combining the benefits of small molecule drugs with the advantages conferred by cooperative interactions with a presenter protein, TrueGlues offer the potential to address the most challenging targets in a tissue-localized manner.
Since their discovery more than three decades ago, molecular glues have demonstrated vast potential to treat human disease.
Recent advancements in the field have largely focused on targeted protein degradation, leaving the expansive potential of molecular glues untapped. Magnet is reimagining what’s possible with molecular glues by venturing beyond known protein-protein interactions (PPIs) and analyzing the broad protein landscape to pair target proteins with endogenous presenter proteins for maximum therapeutic impact.
Uniquely enabled by its platform capabilities, Magnet is pioneering the discovery of novel molecular glue medicines to address a range of indications with high unmet need, including cancer, immune disorders, and cardiovascular disease.
Rationally designed TrueGlues localize drug effects to disease-relevant tissues, providing unique opportunities to maximize the therapeutic index by minimizing on-target-off-tissue toxicity.
TrueGlues offer opportunities to induce biological synergy, target historically undruggable proteins, and alter protein localization to enable mechanisms of action that are not attainable by traditional small molecule inhibitors.
OUR TECHNOLOGY
Building upon recent advances in proteomics, screening, and bioinformatics, we believe the time is now to execute on this long-standing goal of rational molecular glue discovery.
Our TrueGlue discovery platform combines state-of-the-art screening technologies utilizing diverse chemical libraries and human biology–driven target and presenter selection. Our process integrates diverse streams of in-house and external data to discover and exploit novel molecular glue mechanisms of action. Magnet’s TrueGlue technology can be applied in an indication-agnostic manner to discover molecular glues with a wide range of target modulation, drug-like properties, and selectivity.
OUR PEOPLE
Magnet’s team combines decades of drug‑discovery experience and an innovative TrueGlue pipeline.
Our diverse scientific expertise has enabled a multipronged approach that pushes the boundaries of existing technology to advance TrueGlues as a new therapeutic modality with the potential to alter the treatment landscape in cancer, autoimmune, and cardiovascular diseases.
- All
- Leadership
- Team
- Founders
- Board Of Directors
- Scientific Advisory Board
Brian Safina, PhD
President & Chief Executive OfficerBret Williams, PhD
Senior Vice President of ResearchMatthew Hayward, PhD
Vice President of Drug DiscoveryJennifer Franklin
Vice President of OperationsKristina Burow
Managing Director at ARCH Venture PartnersThomas Cahill, MD, PhD
Founder and Managing Partner at Newpath PartnersRamnik Xavier, MD, PhD
Scientific Advisory Board ChairBenjamin F. Cravatt, PhD
Founder & AdvisorDavid A. Spiegel, MD, PhD
Founder & AdvisorMichael Rosbash, PhD
Founder & AdvisorRicha Saxena, PhD
Founder & AdvisorStuart Schreiber, PhD
Founder & AdvisorJoshua Alper, PhD
Biomolecular DiscoveryChelsea Ankeny
Office ManagerAustin Carr, PhD
ProteomicsXiao Chen, PhD
BiologyYiQun Chen
BiologyJessica Gasser, PhD
BiologyShubhroz Gill, PhD
BiologyAdarsh Godbole
Protein ProductionYuan Hu, PhD
Computational ChemistryBruce Hua, PhD
ChemistryLiam Hudson, PhD
ChemistryAnita Kim
Lab OperationsChueh-Ling Kuo, PhD
Biomolecular DiscoveryJason Lowe, PhD
ChemistryAlyssa Lutservitz, MS
InformaticsAshish Maurya, PhD
BiologyJessica McManus
BiologyFrancesca Pisanzio
BiologyJames Ralff
Compound ManagementAndrew Reidenbach, PhD
Biomolecular DiscoveryDavid Rhee, PhD
ProteomicsAnthony Scruse, PhD
ChemistryLuke Stamatakis, CPA
Finance & AccountingTom Tian, PhD
BiologyTiffany Tsang, PhD
BiologyGo Watanabe, PhD
Protein ProductionTeruki Watanabe, PhD
ChemistryLauren Weiss
BiologyHsin-Lan Wen, PhD
BiologyOur Investors
CAREERS
Magnet Biomedicine is building a world-class team to unleash the scientific breakthroughs and expertise of our founders.
We are looking for creative, thoughtful, science-first innovators to join our collaborative team. Come help us realize the potential of molecular glues to achieve the broadest possible impact for patients.